• They are like Thermo Fisher Scientific or Danaher, but specifically providing the high-tech equipment and systems for blood and plasma collection and processing.
• Imagine Becton Dickinson (BD), but specializing in the advanced equipment and software that helps hospitals and blood centers efficiently collect, process, and manage blood products like plasma.

• Plasma Collection Systems: Automated devices used by plasma centers to efficiently collect source plasma for therapeutic use.
• Blood Component Collection Systems: Technologies designed for the automated collection and processing of specific blood components such as platelets, red blood cells, and plasma from donors.
• Cell Salvage Systems: Medical devices used during surgery to collect, process, and reinfuse a patient's own shed blood, thereby reducing the need for allogeneic blood transfusions.
• Hemostasis Analyzers: Diagnostic instruments that provide rapid and comprehensive assessment of a patient's blood clotting function, guiding clinical decisions in critical care and surgery.
• Vascular Closure Devices: Devices used by clinicians to achieve rapid and secure closure of arterial and venous punctures following catheterization procedures, minimizing complications and recovery time.

Haemonetics (HAE) - Major Customers

• Plasma Collection Companies: These are major pharmaceutical companies that operate large networks of plasma collection centers. Haemonetics' automated plasma collection systems (such as the NexSys PCS device) are critical for these companies to efficiently collect plasma, which is then fractionated into life-saving biotherapeutics. Key customers in this segment, often large public companies, include:
  • CSL Limited (ASX: CSL) - operates CSL Plasma.
  • Grifols S.A. (NASDAQ: GRFS) - operates Grifols Plasma.
  • Takeda Pharmaceutical Company Limited (NYSE: TAK) - operates BioLife Plasma Services.
  • Octapharma AG (a large, privately held company) - operates Octapharma Plasma.
• Hospitals and Hospital Systems: These customers utilize Haemonetics' products for various applications including blood management, cell salvage during surgical procedures (e.g., Cell Saver Elite), and hemostasis diagnostics (e.g., TEG Hemostasis Analyzer systems). This category encompasses a vast number of public and private hospitals, as well as integrated delivery networks (IDNs) globally. While no single hospital system typically represents a dominant portion of Haemonetics' revenue, collectively, this segment is a major customer base.
• Blood Banks and Blood Centers: These organizations rely on Haemonetics' blood processing and component preparation systems to efficiently manage and prepare blood products for transfusion.

Christopher Simon, President and Chief Executive Officer

Christopher Simon joined Haemonetics in May 2016. He previously spent over two decades as a Senior Partner at McKinsey & Company, where he led the Global Medical Products Practice. He also held commercial and operating roles at Baxter Healthcare Corporation and served as an Infantry Officer in the U.S. Army. Prior to his appointment, he was the lead partner for McKinsey's strategy review with Haemonetics in 2015, which gave him insights into the company's business and markets and led to his co-architecting its strategic plan.

James C. D'Arecca, Executive Vice President, Chief Financial Officer

James C. D'Arecca joined Haemonetics as Chief Financial Officer in April 2022. Before this, he served as CFO of TherapeuticsMD, a women's healthcare company, from June 2020 to April 2022. He was also Senior Vice President and Chief Accounting Officer at Allergan plc for nearly seven years until its merger with AbbVie Inc. in May 2020. Earlier in his career, he held finance and business development positions at Bausch + Lomb, Merck & Co., Inc., and Schering-Plough, and began his career at PricewaterhouseCoopers with a focus on pharmaceuticals, medical devices, and consumer products.

Michelle L. Basil, Executive Vice President, General Counsel

Michelle L. Basil joined Haemonetics as Executive Vice President and General Counsel in 2017. She brings over 20 years of experience in corporate and securities law, having previously been a partner at Nutter, McClennen & Fish LLP from 1997 to 2017, where her work focused on mergers and acquisitions, securities offerings, and other corporate transactions.

Frank W. Chan, Ph.D., Executive Vice President, Chief Operating Officer

Frank W. Chan, Ph.D. joined Haemonetics as Chief Operating Officer on April 7, 2025. He has over 25 years of leadership experience in the medical device and healthcare technology sectors. Dr. Chan joined Haemonetics from Medtronic plc, where he served as President of the Acute Care & Monitoring business. His prior experience includes various leadership roles at Covidien plc (acquired by Medtronic) and earlier positions at Medtronic and DePuy Orthopaedics, Inc.

Roy Galvin, Executive Vice President, Chief Commercial Officer

Roy Galvin was appointed Executive Vice President, Chief Commercial Officer in March 2025. He initially joined Haemonetics in October 2022 as President, Global Plasma and Blood Center. Prior to Haemonetics, he spent over 25 years at Medtronic plc, holding various leadership roles including Senior Vice President Commercial – US Cranial & Spinal Technologies and Vice President US Sales – Surgical Technologies. His career also includes roles at Xomed ENT (before its acquisition by Medtronic), Corin Orthopedics, Biomet Corporation, and Zimmer Orthopedic.

Haemonetics (HAE) operates in several key medical technology markets. The addressable market sizes for their main products and services are as follows:

• Plasma-Based Therapeutics: The global addressable market for plasma-based therapeutics was estimated at $28.12 billion in 2024. This market is projected to grow to $43.91 billion by 2031, with a compound annual growth rate (CAGR) of 6.32% during that period.
• Hemostasis Diagnostics: The global hemostasis diagnostics market was valued at approximately $1.16 billion in 2024. It is forecast to reach $1.49 billion by 2030, growing at a CAGR of 4.5% from 2025 to 2030. North America held the largest share of this market in 2024, accounting for 38.84%. More broadly, the global hemostasis market (which may include agents beyond diagnostics) was valued at $3.70 billion in 2024 and is expected to reach $5.17 billion by 2034, growing at a CAGR of 3.40%.
• Interventional Technologies (Optical Sensor Guidewires): The addressable market for optical sensor guidewires, a segment within Haemonetics' interventional technologies (added through the OpSens acquisition), is valued at $1.1 billion. The region for this market size is global, with Haemonetics' technological solutions in endovascular surgery being actively used in the U.S.
• Blood Center Products: null
• Surgical Blood Salvage (Cell Salvage): null
• Transfusion Management: null

Haemonetics (HAE) Expected Drivers of Future Revenue Growth

Haemonetics Corporation (HAE) is poised for future revenue growth over the next 2-3 years, primarily driven by several key strategic initiatives and market dynamics:

1. Strong Performance and Expansion in the Hospital Business: Haemonetics expects continued robust growth from its Hospital business segment, particularly in Vascular Closure and Hemostasis Management. This growth is anticipated through increased utilization of products like TEG 6s disposables, price increases, and the expansion of the U.S. installed base for Hemostasis Management. The recent FDA clearance for their global hemostasis heparin neutralization cartridge and the positive reception of the VASCADE MVP XL device in vascular closure are also expected to contribute significantly.
2. Organic Growth and Market Share Gains in the Plasma Business: Despite the impact of the CSL contract wind-down, Haemonetics projects strong organic growth in its Plasma business. This growth is fueled by market share gains, expansion of global customer relationships, and the leveraging of advanced technologies such as Express Plus and Persona, which aim to improve collection time and center throughput.
3. Strategic Acquisitions: Recent acquisitions are playing a vital role in Haemonetics' revenue expansion. The additions of OpSens and Attune Medical have contributed to growth, particularly within the Hospital business, by expanding the company's product portfolio and market reach in sensor-guided technologies and esophageal protection devices.
4. Ongoing Product Innovation and Research & Development: A consistent focus on innovation and R&D across its product lines is a crucial driver. Haemonetics is committed to developing next-generation solutions in its blood management technologies, plasma, and interventional technologies segments to enhance market share and differentiate its offerings.
5. Favorable Pricing Strategies: The company has cited price increases as a factor in revenue growth within its Hemostasis Management business and has highlighted improved pricing strategies related to key product upgrades in the Plasma segment. These strategic pricing adjustments are expected to continue supporting top-line expansion.